Analgesic effects of a novel monoclonal antibody against Nav1.7 sodium channel

Le résumé fourni par la source

[Background] Neuropathic pain is a complex and chronic disease caused by injury or dysfunction in peripheral and central nervous system. Current analgesics are often inadequate due to the lack of efficacy and dose-limiting side effects. The voltage-gated sodium channel Nav1.7 is preferentially expressed in peripheral sensory neurons, and humans that lack this channel are completely insensitive to pain. In this viewpoint, Nav1.7 inhibitors could be promising analgesics for a broad range of pain conditions. However the search of Nav1.7-specific inhibitor has not been successfully progressed because small molecules are limited to have high selectivity in high sequence similarity among Nav channel subtypes. Here, we present a monoclonal antibody which binds Nav1.7-specific extracellular domain and reduces pain behaviors.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.